Immune checkpoint therapy regulates endothelial cell functions and reverses the immunosuppressive effects of VEGF in metastatic melanoma by decreasing intratumoral VEGF(R2) expression and consecutively activating CD8 + T cells via the IFNγ signalling pathway [17,18,41]. The gene discussed is CD8A; the disease is metastatic melanoma.